TVA Medical, Inc. today announced several clinical updates involving its everlinQ™ endoAVF System, an innovative endovascular technique to create hemodialysis access without open surgery, with other potential clinical applications. The everlinQ endoAVF System has European CE Mark and Health Canada Medical Device License for end-stage renal disease (ESRD) patients who need hemodialysis, and commercialization has begun at select centers in Europe. It is not commercially available in the United States and is currently under review by the U.S. Food and Drug Administration. (read more)